肝硬化和肝癌病人血sIL—2R与肝纤维化的关系

我们测定了原发性肝癌(Hepatocellular Carcino-ma,HCC)和肝硬化(Liver Cirrhosis,LC)病人外周血中可溶性白介素Ⅱ受体(sIL—2R)、人Ⅲ型前胶原(hPcⅢ)、透明质酸(HA)、ALT、γ—GTT的水平的变化,并分析了它们之间的相互关系,试图了解IC和HCC患者外周血sIL—2R与肝纤维化的关系。 材料和方法 一、对象:经临床诊断的病毒性肝炎后肝硬化(LC)病人47例(男35,女12),年龄21～74岁,平均51.4岁。伴肝硬化的原发性肝癌(HCC)病人29例(男19,女10),年龄31～70岁,平均55.6岁(1977年全国肝癌协作会议制定的肝癌诊断标准)。正常对照选健康人24例(男19,女5),年龄23～72岁,平均49.7岁。     

不同分级肝硬化患者甲状腺素、血清CA125及肝纤维化指标的临床研究

目的:观察不同分级肝硬化患者甲状腺素、血清CA125及肝纤维化指标的水平。方法:选择我院就诊的肝硬化患者53例作为观察组,按Child-Pugh评分分级,另外选取同期来我院的健康体检者28例作为对照组,检测患者的甲状腺素、血清CA125及肝纤维化指标。结果:甲状腺素含量随着肝硬化级别的增加逐渐降低,血清CA125、血清肝纤维化指标含量随着肝硬化级别的增加逐渐增高,组间差异均有统计学意义(P0.05)。结论:肝硬化患者甲状腺素、血清CA125及肝纤维化指标的水平能够反应病情的轻重程度,值得临床关注。     

肝纤维化、肝硬化的基因治疗

肝纤维化、肝硬化是威胁人类健康的重大疾病。近年来有关肝纤维化、肝硬化发生发展的主要分子生物学和遗传学事件相继阐明 ,人类对肝纤维化、肝硬化进程的认识深入到分子水平 ,为肝纤维化、肝硬化的基因治疗奠定了基础。本文综述三年来肝纤维化、肝硬化基因治疗的研究进展     

肝纤维化、肝硬化的基因治疗

肝纤维化、肝硬化是威胁人类健康的重大疾病,近年来有关肝纤维化、肝硬化发生发展的主要分子生物学和遗传学事件相继阐明,人类对肝纤维化、肝硬化进程的认识深入到分子水平,为肝纤维化、肝硬化的基因治疗奠定了基础,本综述三年来肝纤维化,肝硬化基因治疗的研究进展。     

肝硬化患者血清毒素与肝纤维化标志物的相关性的临床研究

目的 探讨不同Child-pugh分级肝硬化患者血清内毒素与肝纤维化标志物的相关性。方法 对101例不同Child-pugh分级肝硬化患者采用偶氮基质显色法检测血清内毒素，放免和固相酶免疫法测定肝纤维化标志物HA、PCⅢ、LN、IV-C水平。结果 肝硬化患者血清HA、PCⅢ、LN、IV-C水平明显高于健康对照组（P〈0．05或P〈0．01）。不同Child．pugh分级肝硬化患者均存在不同程度的内毒素血症，内毒素水平随着Child．pugh分级的逐渐升高明显递增，血清HA、PCⅢ、LN、IV-C水平也显著增加，二者呈明显正相关。结论 肝硬化患者血清内毒素水平与肝纤维化标志物水平呈正相关，防治内毒素血症有利于缓减肝纤维化进程及改善预后。     

肝硬化肝门静脉血流超声测定与肝纤维化指标的比较

目的：探讨肝门静脉血流和肝纤维化指标对诊断肝硬化的诊断价值。方法：50例肝硬化患者和20例正常对照组用肝门静脉超声和放免法分别测定肝门静脉血流和肝纤维化指标。结果：肝硬化肝门静脉血流动力学指标均高于正常对照组（P〈0．05），并随着肝功能Child Puph分级程度严重而下降；活动性肝纤维化指标明显高于静止性肝硬化（P〈0．05～0．01）；超声与血清判断肝硬化的符合率比较大致相同。结论：肝门静脉超声和肝纤维化指标能判断肝硬化损害的程度。     

蛋白C、蛋白S、抗凝血酶、凝血因子Ⅷ在不同Child-Pugh肝功能分级的慢性肝硬化患者中的应用研究

目的 探讨血浆蛋白C(protein C,PC)、血浆蛋白S(protein S,PS)、血浆抗凝血酶(antithrombin, AT)、血浆凝血因子Ⅷ(coagulation factor Ⅷ,F Ⅷ)在不同Child-Pugh肝功能分级的慢性肝硬化患者中的应用意义。方法 选取2020年12月至2021年12月首都医科大学附属北京佑安医院进行诊治的96例慢性肝硬化患者作为研究对象,另选择同期体检正常的15例正常人作为对照组,分别采用发色底物法和凝固法测定不同Child-Pugh肝功能分级患者的PC、PS、AT、FⅧ等水平并进行比较,并分析相关性。结果 蛋白C、蛋白S、AT、FⅧ在不同Child-Pugh肝功能分级的分组间有显著差异。随着Child-Pugh肝功能分级变差,患者的蛋白C、蛋白S和AT的活性明显降低,FⅧ活性增加。结论慢性肝硬化有高凝风险,建议检测和评估血栓形成的可能。     

肝硬化患者血清中AST、ALT比值与HA相关性的临床研究

目的 探讨不同Child-Pugh分级肝硬化患者血清中AST、ALT比值与肝纤维化标志物HA的相关性.方法 对96例不同Child-Pugh分级肝硬化患者采用重氮法检测血清AST、ALT比值,放射免疫法测定肝纤维化标志物HA水平.结果 肝硬化患者血清AST、ALT比值,HA水平均明显高于健康对照组(P<0.001) .不同 Child-Pugh分级肝硬化患者AST、ALT比值均有所不同,AST、ALT比值随着 Child-Pugh分级的逐渐升高明显递增,血清肝纤维化标志物HA水平也显著增加,二者呈明显正相关.结论 肝硬化患者AST、ALT比值与肝纤维化标志物HA水平呈正相关(r=0.435,P<0.001),维护一定水平的肝功能,降低AST、ALT比值有利于减缓肝纤维化进程及改善预后.     

肝硬化患者胆囊超声表现与血流动力学、肝功能和Child-Pugh分级的关系

目的:探讨肝硬化患者胆囊超声影像特点以及与肝脏血流动力学、肝功能和Child-Pugh分级之间的关系.方法:回顾性分析2015年9月至2019年8月在我科就诊的96例肝硬化患者及83例非肝硬化体检者的资料,观察胆囊彩色多普勒超声的不同表现;分析肝硬化病人胆囊壁厚度与门静脉宽度、血清白蛋白、Child-Pugh分级之间的...     

乙型肝炎肝硬化患者乙型肝炎病毒DNA水平与肝纤维化程度的关系

目的 探讨乙型肝炎肝硬化患者乙型肝炎病毒(HBV)DNA水平与肝纤维化程度的关系及其临床意义.方法 回顾性分析2004年至2006年本科室收治的263例乙型肝炎肝硬化住院患者的临床资料.所有患者均进行肝功能Child-Pugh分级,检测HBV DNA、HBV血清标志物、透明质酸(HA)、人Ⅲ型前胶原(Hpc-Ⅲ)、Ⅳ型胶原(Ⅳ-C)、层粘蛋白(LN);行腹部超声检测脾大小、门静脉内径、脾静脉内径;胃镜检查食管静脉曲张程度,并记录常见并发症.根据HBV DNA水平分为4组:G1组,HBV DNA＜103拷贝/ml;G2组,HBV DNA 103～＜105拷贝/ml;G3组,HBV DNA 105～＜107拷贝/ml;G4组,HBV DNA≥107拷贝/ml.比较各组间Child-Pugh分级、肝纤维化血清指标和门脉高压指标的差异以及各组肝硬化常见并发症的发生情况.结果 263例患者中217例(82.5%)HBV DNA阳性.不同HBV DNA水平患者之间的Child-Pugh评分分级、HA、Hpc-Ⅲ、Ⅳ-C、LN比较,差异无统计学意义(均P＞0.05).4组患者之间脾大小、门静脉内径、脾静脉内径及食管静脉曲张程度比较,差异无统计学意义(均P＞0.05).4组患者并发症如消化道出血、继发感染、腹水、肝性脑病、肝癌等发生率差异也无统计学意义(均P＞0.05).结论 绝大部分乙型肝炎肝硬化患者HBV DNA阳性,但血清HBV DNA水平高低与肝硬化严重程度及并发症的发生率无明显关联.     

肝细胞癌和肝硬变中bcl-2蛋白表达与细胞凋亡的关系

目的：研究肝细胞癌和肝硬变中ｂｃｌ－２蛋白表达与细胞凋亡的关系。方法：应用原位脱氧核糖核酸末端转移酶标记法和Ｓ－Ｐ免疫组化技术检测２８例肝硬变和３５例肝细胞癌组织中凋亡细胞的分布、密度及ｂｃｌ－２蛋白的表达。结果：肝细胞癌组织中凋亡细胞密度显著低于肝硬变，且随其恶性程度的增高呈逐渐降低趋势；凋亡细胞在肝硬变中多分布于假小叶周边区域。ｂｃｌ－２蛋白在肝细胞癌组织中的表达强度明显高于肝硬变，但表达的阳性率差异不明显。结论：ｂｃｌ－２通过其表达产物调控肝硬变和肝细胞癌中的细胞凋亡，在肝细胞癌发生中起重要作用，但ｂｃｌ－２蛋白并非细胞凋亡的唯一调控因素     

可溶性细胞间黏附分子-1在原发性肝癌患者血清中的表达及其与肝纤维化的关系

目的:探讨可溶性细胞间黏附分子-1(sICAM-1)在原发性肝癌(PHC)患者血清中的水平及其与肝纤维化的关系。方法:采用ELISA方法测定45例PHC患者、30例良性肿瘤患者和35例健康查体者血清sICAM-1和肝纤维化四项(PCⅢ、Ⅳ-C、LN、HA)水平,并分析sICAM-1与肝纤维化之间的关系。结果:PHC组血清sICAM-1和肝纤维化四项(PCⅢ、Ⅳ-C、LN、HA)水平均显著高于良性肿瘤组和正常对照组,相比较有显著性差异(P<0.05);而良性肿瘤组和正常对照组各指标比较差异无统计学意义(P>0.05);血清sICAM-1含量与PCⅢ、Ⅳ-C、LN、HA含量呈显著正相关性(r=0.683、0.575、0.573、0.539,P<0.05)。结论:检测血清sICAM-1的水平对判定PHC患者的病情、为肝癌的早期诊断和治疗有着重要的临床意义。     

Diagnosis of hepatocellular carcinoma in patients with liver cirrhosis using liver function assays

Sex, age and 21 routine liver function assays were analyzed by stepwise selection and the best-of-all-possible-combinations method to identify a small group of assays valuable in establishing which liver cirrhosis (LC) patients have a high risk of hepatocellular carcinoma (HCC), when alpha-fetoprotein (AFP) is not elevated. Data was obtained from 115 HCC and 122 LC patients on admission. Tumor size correlated with AFP (0.73), alkaline phosphatase (ALP, 0.47), leucine aminopeptidase (LAP, 0.42), lactic dehydrogenase (LDH, 0.42), and the glutamic oxaloacetic transaminase (GOT)/glutamic pyruvic transaminase (GPT) ratio (GOT/GPT, 0.41). The mean of the correct diagnosis rates (CDR) of HCC and LC utilizing AFP as the sole parameter (89%) was markedly higher than those of the other parameters. The best-of-all-possible-combinations method presented a more powerful combination than stepwise selection. The best combination of 7 parameters (LAP, GOT/GPT, choline esterase, one-hour erythrocyte sedimentation rate, age, albumin/globulin ratio, and total bilirubin) presented a mean CDR of 80%, HCC CDR of 77%, and false positive rate of 18%. LC patients statistically diagnosed as having HCC by these 7 parameters are proposed as high risk patients. Fourteen (78%) of 18 HCC patients who were AFP-negative were statistically diagnosed. This analysis can be applied to LC patients to distinguish those that should be followed closely by imaging diagnostic techniques.     

Aetiology of cirrhosis, hepatic fibrosis, and hepatocellular carcinoma.

Histological study of 69 cases of cirrhosis, 9 of severe generalised hepatic fibrosis, and 19 of hepatocellular carcinoma showed an association with alcohol, hepatitis B surface antigen (HBsAg) or a1-antitrypsin bodies in, respectively, 41 (cirrhosis), 5 (fibrosis), and 9 (carcinoma). Eight of the cirrhotic cases and two of the carcinoma cases had double associations, HBsAg being present in all. Torcein and aldehyde fuchsin staining gave both false positive and false negative results when compared with immunofluorescence and immunoperoxidase methods for HBsAg. Large amounts of copper were found in four cirrhotic livers, and moderate amounts in 13: the diagnostic value of copper staining is questioned.     

Interferon-gamma is associated with hepatic dysfunction in fibrosis,cirrhosis, and hepatocellular carcinoma

The relation between interferon–gamma (IFN-γ) levels and the severity of liver diseases through fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) has not been fully clarified. Thus, we aimed to characterize IFN-γ levels in liver-diseased patients. IFN-γ levels were determined by Western-blot and ELISA in sera from 30 healthy individuals, 53 patients with non-significant fibrosis (F0-F1), 47 with moderate/severe fibrosis (F2-F3), 44 cirrhotic patients (F4), and 50 with HCC. Enhanced levels of IFN-γ were associated with the progression of liver disease. The differences were statistically significant (P < 0.0001) when patients with F2-F3, F4, or HCC were compared with F0-F1 or healthy controls. The increase in IFN-γ was associated with HCC (OR = 0.98, 95% CI 0.97–0.99, P = 0.002). There was no statistically significant association between IFN-γ levels and HCV-RNA (IU/ml) (r = 0.1, P = 0.43) or HCV-NS4 (µg/mL) (r = 0.1, P = 0.17). There was significant (P < 0.0001) association between IFN-γ levels and the fibrosis stages and activity, albumin, platelet count, total bilirubin, and international normalized ratio (INR). In conclusion, elevated concentrations of IFN-γ represent a characteristic feature of liver disease severity regardless of underlying disease. Significant correlations with indices of hepatic dysfunction suggest that enhanced IFN-γ levels represent a consequence of liver dysfunction rather than of inflammatory disease.